Trial Profile
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MOONLIGHT
- 24 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Mar 2024.
- 24 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.
- 06 Jun 2023 Results (n=83) presented at the 59th Annual Meeting of the American Society of Clinical Oncology